Rosa Isela Gallagher

Rosa Isela Gallagher


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2011
Verified
Book Chapter
Closed access
PDF file
RGRosa Isela Gallagher
Rosa Isela Gallagher
SBSteven R. Blakely
Steven R. Blakely
LLLance A. Liotta
Lance A. Liotta
VEVirginia Espina
Virginia Espina

11 December 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
RGRosa Isela Gallagher
Rosa Isela Gallagher
JWJulia Wulfkuhle
Julia Wulfkuhle
DWDenise M. Wolf
Denise M. Wolf
LBLamorna Brown-Swigart
Lamorna Brown-Swigart
CYChristina Yau
Christina Yau
EPEmanuel F. Petricoin
Emanuel F. Petricoin
Molecular subtyping of breast cancer is based mostly on HR/HER2 and gene expression-based immune, DNA repair deficiency, and luminal signatures. We extend this description via functional protein pathway activation mapping using pre-treatment, quantitative expression data from 139 proteins/phosphoproteins from 736 patients across 8 treatment arms of the I-SPY 2 Trial (ClinicalTrials.gov: NCT01042379). We identify predictive fit-for-purpose, mechanism-of-action-based signatures and individual predictive protein biomarker candidates by evaluating associations with pathologic complete response. Elevated levels of cyclin D1, estrogen receptor alpha, and androgen receptor S650 associate with non-response and are biomarkers for global resistance. We uncover protein/phosphoprotein-based signatures that can be utilized both for molecularly rationalized therapeutic selection and for response prediction. We introduce a dichotomous HER2 activation response predictive signature for stratifying triple-negative breast cancer patients to either HER2 or immune checkpoint therapy response as a model for how protein activation signatures provide a different lens to view the molecular landscape of breast cancer and synergize with transcriptomic-defined signatures.

30 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Karen E. PollokKaren E. Pollok
Karen E. Pollok
AJAsha Jacob Jannu
Asha Jacob Jannu
KBKhadijeh Bijangi-Vishehsaraei
Khadijeh Bijangi-Vishehsaraei
EDErika A. Dobrota
Erika A. Dobrota
BBBarbara J. Bailey
Barbara J. Bailey
Karen E. PollokKaren E. Pollok
Karen E. Pollok
Establishment of clinically annotated, molecularly characterized, patient-derived xenografts (PDXs) from treatment-naïve and pretreated patients provides a platform to test precision genomics-guided therapies. An integrated multi-OMICS pipeline was developed to identify cancer-associated pathways and evaluate stability of molecular signatures in a panel of pediatric and AYA PDXs following serial passaging in mice. Original solid tumor samples and their corresponding PDXs were evaluated by whole-genome sequencing, RNA-seq, immunoblotting, pathway enrichment analyses, and the drug–gene interaction database to identify as well as cross-validate actionable targets in patients with sarcomas or Wilms tumors. While some divergence between original tumor and the respective PDX was evident, majority of alterations were not functionally impactful, and oncogenic pathway activation was maintained following serial passaging. CDK4/6 and BETs were prioritized as biomarkers of therapeutic response in osteosarcoma PDXs with pertinent molecular signatures. Inhibition of CDK4/6 or BETs decreased osteosarcoma PDX growth (two-way ANOVA, p < 0.05) confirming mechanistic involvement in growth. Linking patient treatment history with molecular and efficacy data in PDX will provide a strong rationale for targeted therapy and improve our understanding of which therapy is most beneficial in patients at diagnosis and in those already exposed to therapy.